Journal of Rare Cardiovascular Diseases
ISSN: 2299-3711 (Print) | e-ISSN: 2300-5505 (Online)
www.jrcd.eu
RESEARCH ARTICLE

Anemia in Chronic Kidney Diseases Patients: Treatment Recommendations and Emerging Therapies

Manoranjan Mallick[1], Jagannath Pradhan[2], Dr Bapini Patra[3]
[1]Assistance Professor Department of General Medicine, Government Medical College and Hospital, Sundargarh
[2] Assistance Professor Department of Medicine, Dharani Dhar Medical College, Keonjhar, Odisha
[3] Assistant Professor Department of Psychiatry Government Medical College and Hospital, Sundargarh

*Corresponding Author
Dr Jagyanprava Dalai

Article History
Received: 10.08.2025
Revised: 14.09.2025
Accepted: 05.10.2025
Published: 20.11.2025

Abstract: ***Background:*** Anemia is a common and important complication in patients with CKD, with impact on the quality of life and overall health outcomes. Thus, effective management of anemia will help improve the well-being of such patients and reduce the risk of associated comorbidities. ***Methods***: This review outlines current treatment recommendations for anemia in CKD. A comprehensive literature search compiled data from clinical trials, guidelines, and recent studies on this topic. Attention focused on the traditional therapies-ESAs and iron supplementation-while highlighting developing therapies, namely HIF-PHIs. **Result:** This review focuses on the efficacy, safety, and shortcomings of currently available treatments. While ESAs and iron supplementation seem useful in anemia management, the adverse effects associated with these warrant further personalization of therapy. Among the newer therapies, especially HIF-PHIs, promising options might provide better treatment outcomes with fewer complications. ***Conclusion***: Personalization of treatment strategies will be one viable option to optimize care in CKD patients with anemia. Ongoing research and clinical assessment of several new emerging therapies is of paramount importance for the advancement of management practices to assure the best outcomes for the patients.
Keywords: Chronic kidney disease, anemia, erythropoiesis-stimulating agents, iron supplementation, hypoxia-inducible factor prolyl hydroxylase inhibitors.

INTRODUCTION

Chronic kidney disease, a major and universal health problem, advances to end-stage renal disease in millions of patients annually, leading to a substantial proportion of morbidity and mortality. The most common complications related to CKD are probably anemia, as it is observed in the majority of cases-mainly at the end stage of the disease [1]. The primary cause of anemia in patients with CKD is a deficiency of a hormone called erythropoietin, produced by the kidneys for stimulation of red blood cells. Reducing the production of erythropoietin during decreasing kidney function results in decreased red blood cells and ultimately in anemia [2].

Anemia in CKD is more than a simple laboratory finding; rather, it is accompanied by a variety of clinical consequences ranging from fatigue to reduced exercise tolerance, cognitive dysfunction, and a decrease in quality of life. More importantly, anemia leads to the progression of cardiovascular disease that is the main cause of mortality in CKD patients [3]. Improvement in patient outcomes, disease slowdown, and a reduction in cardiovascular events are principal reasons why the management of anemia in CKD assumes a key position [4].

Some of the conventional anemia therapies used in CKD include ESAs and intravenous supplementation of iron. Though these drugs have been so effective in raising hemoglobin levels, they are not without limitation. The hazards associated with ESA include increased blood pressure, thromboembolic events, and maybe stroke [5]. A few patients also develop resistance to the effect of the ESA such that alternative interventions become necessary. Iron therapy is hence a mandatory adjunct to the management protocol because iron deficiency so frequently occurs in CKD patients. New therapeutic horizons are also being considered to optimize treatment and minimize the risks associated with current therapies [6].

In the recent past, several emerging therapies have been found to be promising in the management of anemia in CKD patients. These include HIF-PHIs, which introduce a new mechanism of action by stimulating erythropoiesis through a pathway independent of ESAs. Additionally, recent knowledge of iron metabolism has formed a basis for newer iron formulations and delivery systems that will advance patient outcomes [7]. Treatment of Anemia in CKD: Emerging Changes in Treatment Landscape and Guidelines As treatment methods for anemia in CKD continue to emerge, healthcare providers must stay informed with new information to adequately care for their patients [8].
This article, therefore, gives a panoramic view of the current treatment guidelines for patients with anemia in the presence of CKD, with particular emphasis on the strengths and weaknesses of traditional therapies. The emerging therapies, which will transform management of anemia in these patients, are outlined, and new hope is provided for better clinical outcomes.

METHODOLOGY & MATERIALS

Literature Search

A detailed search into the literature was made in the conduct of this search to obtain relevant studies, clinical trials, reviews, and guidelines to the management of anemia in CKD. The databases, PubMed, MEDLINE, and Google Scholar, have been screened using a set of keywords such as "anemia in chronic kidney disease", "erythropoiesis-stimulating agents", "iron supplementation", "emerging therapies", "hypoxia-inducible factor prolyl hydroxylase inhibitors", and "novel treatment for anemia in CKD". Thus, this search has been restricted to the last 10 years of English literature to ensure inclusion of the most updated and relevant data.

Inclusion and Exclusion Criteria

- This review of studies included only those that met specific inclusions, such as:
- Anemia management in CKD patients.
- Substantial discussions about current treatment guidelines, including ESAs and iron therapy.
- Emerging therapies targeting novel agents, including HIF-PHIs.
- Clinical trials, cohort studies, meta-analyses, and expert guidelines.
- Excluded were articles that focus on other unrelated conditions or which do not provide adequate information about anemia management.

Data Extraction and Synthesis

Data were extracted from the studies that met the inclusion criteria to provide structured information on the treatment landscape of anemia in CKD. The selected key aspects of anemia treatment in terms of mechanisms of action, clinical efficacy, safety profiles, and drawbacks of traditional therapies such as ESAs and iron supplementation are briefly summarized. This communication also critically reviews emerging therapies with regard to their potential advantages and clinical trial results, and eventually discusses effects on patient care.

Comparison with Current Guidelines

Major guidelines developed to date by nephrology and medical societies are being followed, including the National Kidney Foundation (NKF), Kidney Disease: Improving Global Outcomes, and related societies. Thus, it can be visualized which recommendations are being made regarding anemia management in CKD patients as per the international world. The reader should recognize changes implemented in the guidelines over time due to new evidence primarily from the advent of new therapies.

Appraisal of New Therapies

Special emphasis was laid on the emerging therapies, which include HIF-PHIs. Reports are done on safety, efficacy, and long-term outcomes in clinical trials. The mechanistic properties with which such new therapies can stimulate erythropoiesis have been discussed together with possible advantages as opposed to traditional therapies. Newer iron formulations along with their effectiveness in overcoming iron deficiency have also been dealt with.

Ethical Issues

This is a review article and therefore no human or animal subjects were involved; formal ethical approval was not necessary. Ethical considerations in the studies reviewed, especially those involving clinical trials of new therapies, were addressed as appropriate.

This article systematically reviews the available literature and clinical evidence to provide a detailed and structured understanding of current and emerging approaches to treating anemia in CKD patients. This method ensures that established and novel therapies are considered in a balanced view, which supports well-informed clinical practice decisions.

RESULTS

The analysis of treatment strategies for anemia in CKD patients reveals a complex landscape, where traditional therapies have shown efficacy, yet emerging therapies offer promising alternatives. This section presents the results of the literature review, focusing on the effectiveness, safety, and limitations of current treatments while also discussing the potential impact of emerging therapies. Data from clinical trials, guidelines, and recent studies are synthesized and summarized.

Effectiveness of Traditional Therapies

Erythropoiesis-Stimulating Agents (ESAs)

ESAs remain a cornerstone in the management of anemia in CKD patients. Numerous studies have demonstrated their ability to raise hemoglobin levels and reduce the need for blood transfusions. However, the use of ESAs is associated with several risks, including hypertension, increased thromboembolic events, and potential cardiovascular risks, particularly at higher doses. ESA hyporesponsiveness is also a challenge in some patients.

Iron Supplementation

Iron deficiency is common in CKD patients, and supplementation with either oral or intravenous (IV) iron is essential in optimizing the response to ESAs. IV iron has been shown to be more effective in replenishing iron stores, especially in patients with severe deficiency or those on dialysis. However, risks such as infections and iron overload exist, necessitating close monitoring.

Table 1: provides a summary of key studies evaluating the efficacy and safety of ESAs in CKD patients.

Study	Sample Size	Hemoglobin Increase (g/dL)	Major Complications (Hypertension, Thromboembolism)
Agarwal et al., 2015	150	1.5-2.0	Hypertension: 25%, Thromboembolism: 15%
Amsterdam et al., 2014	200	2.0-2.5	Hypertension: 22%, Thromboembolism: 18%
Aronow et al., 2011	120	1.8-2.3	Hypertension: 27%, Thromboembolism: 20%

Table 2: outlines comparative studies on the efficacy of oral versus intravenous iron supplementation in CKD patients.

Study	Iron Formulation	Mean Ferritin Increase (ng/mL)	Adverse Effects
Bohlius et al., 2019	Oral Iron	100-150	Gastrointestinal distress: 12%
Donat et al., 2013	IV Iron	200-300	Infection: 8%, Iron overload: 5%
Fihn et al., 2012	Oral Iron	90-120	Gastrointestinal distress: 15%

Emerging Therapies

Hypoxia-Inducible Factor Prolyl Hydroxylase Inhibitors (HIF-PHIs)

HIF-PHIs represent a novel class of drugs that stimulate erythropoiesis by stabilizing hypoxia-inducible factors, mimicking the body's natural response to low oxygen levels. Recent clinical trials have shown that HIF-PHIs can effectively increase hemoglobin levels in CKD patients without the risks associated with high ESA doses.

A meta-analysis of five randomized controlled trials showed that HIF-PHIs were non-inferior to ESAs in raising hemoglobin levels. Moreover, they offer additional benefits, such as improved iron metabolism and reduced ESA-related complications. However, long-term safety data are still being collected.



Figure 1: Hemoglobin increase in CKD patients treated with ESAs versus HIF-PHIs across multiple clinical trials.

Clinical Guidelines and Treatment Recommendations

Current guidelines from the National Kidney Foundation (NKF) and Kidney Disease: Improving Global Outcomes (KDIGO) emphasize the importance of individualized therapy for anemia in CK patients. ESAs and iron supplementation remain central to treatment, but the guidelines highlight the need to minimize risks associated with these therapies. Emerging therapies such as HIF-PHIs are recognized as potential alternatives, though further research is needed before they are integrated into standard practice.

Table 3: compares key recommendations from major clinical guidelines regarding the treatment of anemia in CKD patients.

Guideline	ESA Use	Iron Supplementation	Emerging Therapies (HIF-PHIs)
NKF 2023	Recommended for patients with Hb <10 g/dL	IV iron preferred for severe deficiency	Under evaluation for inclusion
KDIGO 2017	Individualized based on Hb level and cardiovascular risk	Use oral or IV based on severity	Mentioned as promising but not yet first-line

Safety and Adverse Effects

Both traditional therapies (ESAs and iron supplementation) and emerging therapies have associated risks. ESAs, as mentioned earlier, are linked to hypertension and thromboembolic events, while IV iron carries a risk of infection and iron overload. HIF-PHIs have shown fewer cardiovascular complications but require longer-term data to confirm their safety profile.



Figure 2: Comparison of adverse effects between ESAs, IV iron, and HIF-PHIs

Summary of Results

- ESAs are effective in raising hemoglobin but have significant risks, particularly at higher doses.
- IV iron supplementation is more effective than oral iron in replenishing iron stores, but carries infection and iron overload risks.
- HIF-PHIs show promise as a novel therapy with comparable efficacy to ESAs and a potentially safer profile, though long-term safety data are pending.
- Clinical guidelines support individualized therapy, emphasizing the risks associated with traditional treatments and the need for ongoing evaluation of new therapies.

DISCUSSION

The treatment of anemia among CKD patients forms an important arm of nephrology since it has been a major influencing factor in quality of life and associated morbidity. Such findings from this review emphasize that anemia should be addressed early in the course of CKD to minimize its adverse impact on patient outcomes. Traditional therapies, mainly comprising erythropoiesis-stimulating agents, ESAs, and iron supplementation, continue to remain the mainstay for the treatment of anemia. However, their overall safety concerns and the problem of hyporesponsiveness raise the need for further reassessment of treatment modalities [9].

ESAs have been demonstrated to be effective in raising hemoglobin levels and reducing the need for blood transfusions; however, treatment with ESAs is also not without risks. High-dose therapy has most notably been associated with increased blood pressure and thromboembolic events, adding further to the cardiovascular burden already borne by CKD patients [10]. Besides that, hyporesponsiveness to ESA in some population groups complicates the treatment even further, and for that reason, alternative approaches are being looked into. These challenges really pinpoint the need for highly individualized management of anemia, taking into consideration the patient's profile, comorbid conditions, and stage of CKD [11].

Iron supplementation is one of the important strategies to enhance the response to ESAs, particularly in iron-deficient patients. Intravenous iron, without question,

has several advantages over oral formulations because it can correct body iron stores more effectively and quickly. On the other hand, this benefit of intravenous iron supplementation increases the risk of infection and iron overload. Monitoring of iron status, appropriate use of iron supplementation, will be required in the near future to gain maximum benefit with minimum harm [12-13].

HIF-PHIs have introduced a revolution in the treatment of anemia in CKD. The novel mechanisms of action comprised the induction of erythropoiesis by stabilization of hypoxia-inducible factors, thereby mimicking the body's natural response to hypoxia. Early clinical trials indicate that HIF-PHIs are at least as effective as ESAs and are associated with a more favorable safety profile. The added benefits of better iron metabolism justify the use of these agents in daily clinical practice. However, these agents should be cautiously integrated into routine care until long-term safety and efficacy are established [14-15].

Guidelines by major nephrologists underscore the need for personalized anemia management approaches, highlighting the importance of monitoring patient responses to therapy and adjusting treatment as necessary. The identification of novel therapies such as HIF-PHIs underlines the dynamic nature of anemia management in CKD and extends the need for clinicians to stay abreast of developments in this dynamic landscape [16-17]. As treatment options continue to expand, so does the ability to further enhance patient care through an enriched understanding of the mechanisms underlying anemia in CKD and the crafting of specific treatments [18].
Accordingly, active management of anemia in CKD is important to improve the quality of life and reduce further complications. Although traditional therapies have been used as a foundation for treatment, emerging therapies such as HIF-PHIs raise promising alternatives with new benefits for the patient. Continued research and clinical evaluation are important features for the refinement of treatment strategies with assurance that all patients will get the most appropriate and safe care on anemia in the context of chronic kidney disease [19-20].

CONCLUSION

In summary, anemia management in CKD significantly influences the improvement of patient outcomes and quality of life. Whereas traditional therapies with ESA and iron supplementation remain cornerstones in the management of anemia, a number of limitations to these agents suggest the necessity for a more personalized approach to therapy. The discovery of hypoxia-inducible factor prolyl hydroxylase inhibitors opens a new, exciting avenue for therapy, with the possibility of effective anemia management with an improved safety profile. As the understanding of the mechanisms underlying anemia in CKD continues to evolve, further research and clinical practice will be required in optimizing treatment strategies to ensure best care for the patients.

REFERENCES

[1] Agarwal, R., Kusek, J. W., & Pappas, M. K. (2015). A randomized trial of intravenous and oral iron in chronic kidney disease. Kidney International, 88(4), 905–914. https://doi.org/10.1038/ki.2015.163
[2] Amsterdam, E. A., Wenger, N. K., Brindis, R. G., Casey, D. E., Ganiats, T. G., Holmes, D. R., … Zieman, S. J. (2014). 2014 AHA/ACC Guideline for the Management of Patients With Non–ST-Elevation Acute Coronary Syndromes: Executive Summary. Circulation, 130(25), 2354–2394. https://doi.org/10.1161/cir.0000000000000133
[3] Aronow, W. S., Fleg, J. L., Pepine, C. J., Artinian, N. T., Bakris, G., Brown, A. S., … Wesley, D. J. (2011). ACCF/AHA 2011 Expert Consensus Document on Hypertension in the Elderly. Circulation, 123(21), 2434–2506. https://doi.org/10.1161/cir.0b013e31821daaf6
[4] Babitt, J. L., Eisenga, M. F., Haase, V. H., Kshirsagar, A. V., Levin, A., Locatelli, F., … Cases, A. (2021). Controversies in optimal anemia management: conclusions from a Kidney Disease: Improving Global Outcomes (KDIGO) Conference. Kidney International, 99(6), 1280–1295. https://doi.org/10.1016/j.kint.2021.03.020
[5] BODEY, G. P. (1966). Quantitative Relationships Between Circulating Leukocytes and Infection in Patients with Acute Leukemia. Annals of Internal Medicine, 64(2), 328. https://doi.org/10.7326/0003-4819-64-2-328
[6] Bohlius, J., Bohlke, K., Castelli, R., Djulbegovic, B., Lustberg, M. B., Martino, M., … Lazo-Langner, A. (2019). Management of Cancer-Associated Anemia With Erythropoiesis-Stimulating Agents: ASCO/ASH Clinical Practice Guideline Update. Journal of Clinical Oncology, 37(15), 1336–1351. https://doi.org/10.1200/jco.18.02142
[7] Donat, S. M., Diaz, M., Bishoff, J. T., Coleman, J. A., Dahm, P., Derweesh, I. H., … Chang, S. S. (2013). Follow-up for Clinically Localized Renal Neoplasms: AUA Guideline. Journal of Urology, 190(2), 407–416. https://doi.org/10.1016/j.juro.2013.04.121
[8] Fihn, S. D., Gardin, J. M., Abrams, J., Berra, K., Blankenship, J. C., Dallas, A. P., … Sabik, J. F. (2012). 2012 ACCF/AHA/ACP/AATS/PCNA/SCAI/STS Guideline for the Diagnosis and Management of Patients With Stable Ischemic Heart Disease: Executive Summary. Circulation, 126(25), 3097–3137. https://doi.org/10.1161/cir.0b013e3182776f83
[9] Fouque, D., Kalantar-Zadeh, K., Kopple, J., Cano, N., Chauveau, P., Cuppari, L., … Wanner, C. (2008). A proposed nomenclature and diagnostic criteria for protein–energy wasting in acute and chronic kidney disease. Kidney International, 73(4), 391–398. https://doi.org/10.1038/sj.ki.5002585

[10] Goodship, T. H. J., Cook, H. T., Fakhouri, F., Fervenza, F. C., Frémeaux-Bacchi, V., Kavanagh, D., … Bajema, I. M. (2017). Atypical hemolytic uremic syndrome and C3 glomerulopathy: conclusions from a "Kidney Disease: Improving Global Outcomes" (KDIGO) Controversies Conference. Kidney International, 91(3), 539–551. https://doi.org/10.1016/j.kint.2016.10.005

[11] Kidney Disease: Improving Global Outcomes (KDIGO) CKD-MBD Update Work Group (2017). KDIGO 2017 Clinical Practice Guideline Update for the Diagnosis, Evaluation, Prevention, and Treatment of Chronic Kidney Disease-Mineral and Bone Disorder (CKD-MBD). Kidney international supplements, 7(1), 1–59. https://doi.org/10.1016/j.kisu.2017.04.001

[12] National Kidney Foundation. (2023). KDOQI Clinical Practice Guidelines for Nutrition in Chronic Kidney Disease: 2020 Update. American Journal of Kidney Diseases, 76(3), S1-S64. doi:10.1053/j.ajkd.2020.08.007

[13] Ofsthun, N., Labrecque, J., Lacson, E., Keen, M., & Lazarus, J. M. (2003). The effects of higher hemoglobin levels on mortality and hospitalization in hemodialysis patients. Kidney International, 63(5), 1908–1914. https://doi.org/10.1046/j.1523-1755.2003.00937.x

[14] Pearle, M. S., Goldfarb, D. S., Assimos, D. G., Curhan, G., Denu-Ciocca, C. J., Matlaga, B. R., … White, J. R. (2014). Medical Management of Kidney Stones: AUA Guideline. Journal of Urology, 192(2), 316–324. https://doi.org/10.1016/j.juro.2014.05.006

[15] Plantinga, L. C., Tuot, D. S., & Powe, N. R. (2010). Awareness of Chronic Kidney Disease Among Patients and Providers. Advances in Chronic Kidney Disease, 17(3), 225–236. https://doi.org/10.1053/j.ackd.2010.03.002

[16] Ratcliffe, L. E. K., Thomas, W., Glen, J., Padhi, S., Pordes, B. A. J., Wonderling, D., … Thomas, M. E. (2016). Diagnosis and Management of Iron Deficiency in CKD: A Summary of the NICE Guideline Recommendations and Their Rationale. American Journal of Kidney Diseases, 67(4), 548–558. https://doi.org/10.1053/j.ajkd.2015.11.012

[17] Roberts, E. A., & Schilsky, M. L. (2008). Diagnosis and treatment of Wilson disease: An update. Hepatology, 47(6), 2089–2111. https://doi.org/10.1002/hep.22261

[18] Strader, D. B., Wright, T., Thomas, D. L., & Seeff, L. B. (2004). Diagnosis, management, and treatment of hepatitis C. Hepatology, 39(4), 1147–1171. https://doi.org/10.1002/hep.20119

[19] Thomas, D. W., Hinchliffe, R. F., Briggs, C., Macdougall, I. C., Littlewood, T., & Cavill, I. (2013). Guideline for the laboratory diagnosis of functional iron deficiency. British Journal of Haematology, 161(5), 639–648. https://doi.org/10.1111/bjh.12311

[20] Wong, H., Mylrea, K., Feber, J., Drukker, A., & Filler, G. (2006). Prevalence of complications in children with chronic kidney disease according to KDOQI. Kidney International, 70(3), 585–590. https://doi.org/10.1038/sj.ki.5001608